Gut power for better health: microbial therapeutics.

IF 2.5 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Current Opinion in Gastroenterology Pub Date : 2025-09-18 DOI:10.1097/MOG.0000000000001136

Eamonn M M Quigley

{"title":"Gut power for better health: microbial therapeutics.","authors":"Eamonn M M Quigley","doi":"10.1097/MOG.0000000000001136","DOIUrl":null,"url":null,"abstract":"Purpose of review: To critically evaluate the literature over the past year on microbial therapeutics in the management of disorders of the large intestine. The primary focus is on disorders where the microbiome has been implicated in pathophysiology, and its modulation has been a therapeutic target.Recent findings: Though widely consumed, data on the impact of probiotics and prebiotics in gastrointestinal disorders continue to pose challenges in interpretation due to shortcomings in study design; postbiotics, meanwhile, because of some logistical and regulatory advantages, are attracting attention. Though time-honored for its role in infections due to Clostridioides difficile (CDI), FMT has encountered challenges in relation to regulation leading to the appearance of highly standardized, extensively screened and rigorously prepared microbial products [defined as live biotherapeutic products (LBP)], which show great promise; two have been approved by the FDA for prevention of recurrent CDI. Outside of CDI, efforts to define a role for FMT in the management of various diseases have met with mixed results.Summary: The translation of findings in studies of microbiome composition to successful therapies has proven disappointing to date, though attempts to develop selective and targeted microbial consortia show promise and may lead the way to personalized bacteriotherapy.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOG.0000000000001136","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To critically evaluate the literature over the past year on microbial therapeutics in the management of disorders of the large intestine. The primary focus is on disorders where the microbiome has been implicated in pathophysiology, and its modulation has been a therapeutic target.

Recent findings: Though widely consumed, data on the impact of probiotics and prebiotics in gastrointestinal disorders continue to pose challenges in interpretation due to shortcomings in study design; postbiotics, meanwhile, because of some logistical and regulatory advantages, are attracting attention. Though time-honored for its role in infections due to Clostridioides difficile (CDI), FMT has encountered challenges in relation to regulation leading to the appearance of highly standardized, extensively screened and rigorously prepared microbial products [defined as live biotherapeutic products (LBP)], which show great promise; two have been approved by the FDA for prevention of recurrent CDI. Outside of CDI, efforts to define a role for FMT in the management of various diseases have met with mixed results.

Summary: The translation of findings in studies of microbiome composition to successful therapies has proven disappointing to date, though attempts to develop selective and targeted microbial consortia show promise and may lead the way to personalized bacteriotherapy.

查看原文本刊更多论文

肠道力量促进健康：微生物疗法。

回顾的目的：批判性地评价过去一年中关于大肠疾病管理中微生物疗法的文献。主要的焦点是在疾病中，微生物组已涉及病理生理，其调节已成为一个治疗目标。近期研究发现：虽然益生菌和益生元对胃肠道疾病的影响被广泛使用，但由于研究设计的缺陷，有关益生菌和益生元的数据在解释上仍然存在挑战；与此同时，由于一些物流和监管方面的优势，后生物制剂正吸引着人们的关注。尽管FMT在艰难梭菌（CDI）感染中的作用由来已久，但它在监管方面遇到了挑战，导致高度标准化、广泛筛选和严格制备的微生物产品（定义为活生物治疗产品（LBP））的出现，这些产品显示出巨大的希望；其中两种已被FDA批准用于预防复发性CDI。在CDI之外，确定FMT在各种疾病管理中的作用的努力取得了不同的结果。摘要：迄今为止，将微生物组组成的研究结果转化为成功的治疗方法已被证明是令人失望的，尽管开发选择性和靶向微生物联合体的尝试显示出希望，并可能引领个性化细菌治疗的道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Gastroenterology 医学-胃肠肝病学

CiteScore

5.30

自引率

0.00%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in Gastroenterology features hand-picked review articles from our team of expert editors. With twelve disciplines published across the year – including gastrointestinal infections, nutrition and inflammatory bowel disease – every issue also contains annotated references detailing the merits of the most important papers.